A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma

• Main Authors: da Silveira Nogueira Lima, J.P, Georgieva, M, Haaland, B, de Lima Lopes, G
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: B Raf kinase; carboplatin; cobimetinib; cytotoxic T lymphocyte antigen 4; dabrafenib; dacarbazine; ipilimumab; mitogen activated protein kinase; nivolumab; paclitaxel; pembrolizumab; placebo; programmed death 1 ligand 1; selumetinib; temozolomide; ticilimumab; trametinib; vemurafenib; immunological antineoplastic agent; Article; cancer immunotherapy; dosage schedule comparison; drug dose comparison; drug efficacy; gene mutation; human; melanoma; meta analysis; molecularly targeted therapy; overall survival; priority journal; progression free survival; qualitative analysis; randomized controlled trial (topic); systematic review; disease free survival; immunotherapy; treatment outcome; Antineoplastic Agents, Immunological; Disease-Free Survival; Humans; Immunotherapy; Melanoma; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/178675
• Institution: National University of Singapore

10.1002/cam4.1001